drugs
publication date
Revenue Cycle
Making the Case for 340B Reforms
Ryan Long, the co-author of a recent USC Schaeffer Center white paper on the 340B Drug Pricing Program, argues that...
Revenue Cycle
AHA Asks DOJ, FTC to Probe Drugmakers for Anticompetitive 340B Tactics
The American Hospital Association says that the timing of drug companies' proposed 340B rebate model suggests a collective effort to...
Innovation
Rethinking the Care Coordination Strategy
Hospitals like Magnolia Regional Health Center are adding nurse navigators to the care management team to focus on specific clinical...
Innovation
AI and Medication Adherence: Training Tech on Bad Behaviors
Pharmacies and providers are turning to AI to better understand why their patients aren?t following doctors? orders on their prescriptions.
Revenue Cycle
Congressional Testimony Highlights Potential Areas for Future Legislative Action
In a recent Senate hearing, expert witnesses argued that the healthcare affordability crisis is driven by a fundamental lack of...
Revenue Cycle
Could This HRSA Pilot Program Signal Future Changes to the 340B Program?
HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its...
Revenue Cycle
Infographic: Are Drug Companies or Hospitals More Likely to Violate 340B Rules?
In a recent analysis of HRSA data, the American Hospital Association has turned the tables on drug companies and accused...
Technology
Can New DEA Leadership Resolve the Telemedicine Prescription Debate?
A widely panned proposal to regulate virtual prescriptions for controlled drugs isn?t going anywhere. It?s time to bring federal regulators...
Payer
The Winning Edge for Employer GLP-1 Cost Containment
Hospitals and health systems must strategically manage rising GLP-1 costs while balancing workforce health and long-term financial sustainability.
Revenue Cycle
CMS Proposes Modest Payment Bump, Major Policy Shifts in 2026 OPPS Proposed Rule
CMS suggests a modest 2.4% payment update in the 2026 Hospital Outpatient Prospective Payment System proposed rule on top of...
Revenue Cycle
AHA Claps Back at Drug Companies in Conflict Over 340B Program
Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report.
CFO
CFO In the Know: Price Transparency Update
Hospital price transparency compliance enforcement is set to rise.